FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2767793022> ?p ?o ?g. }

• W2767793022 endingPage "55" @default.
• W2767793022 startingPage "47" @default.
• W2767793022 abstract "Cancer is a disease that has been the focus of scientific research and discovery and continues to remain so. Polo-like kinases (PLKs) are basically serine/threonine kinase enzymes that control cell cycle from yeast to humans. PLK-1 stands for 'Polo-like kinase-1'. It is the most investigated protein among PLKs. It is crucial for intracellular processes, hence a 'hot' anticancer drug-target. Accelerating innovations in Enzoinformatics and associated molecular visualization tools have made it possible to literally perform a 'molecular level walk' traversing through and observing the minutest contours of the active site of relevant enzymes. PLK-1 as a protein consists of a kinase domain at the protein N-terminal and a Polo Box Domain (PBD) at the C-terminal connected by a short inter-domain linking region. PBD has two Polo-Boxes. PBD of PLK-1 gives the impression of a small clamp sandwiched between two clips, where the two Polo Boxes are the 'clips' and the 'phosphopeptide' is the small 'clamp'. Broadly, two major sites of PLK-1 can be potential targets: one is the adenosine-5'-triphosphate (ATP)-binding site in the kinase domain and the other is PBD (more preferred due to specificity). Targeting PLK-1 RNA and the interaction of PLK-1 with a key binding partner can also be approached. However, the list of potent small molecule inhibitors targeting the PBD site of PLK-1 is still not long enough and needs due input from the scientific community. Recently, eminent scientists have proposed targeting the 'Y'-shaped pocket of PLK-1-PBD and encouraged design of ligands that should be able to concurrently bind to two or more modules of the 'Y' pocket. Hence, it is suggested that during molecular interaction analyses, particular focus should be kept on the moiety in each ligand/drug candidate which directly interacts with the amino acid residue(s) that belong(s) to one of the three binding modules which together create this Y-shaped cavity. This obviously includes (but it is not limited to) the 'shallow cleft'-forming residues i.e. Trp414, H538 and K540, as significance of these binding residues has been consistently highlighted by many studies. The present article attempts to give a concise yet critically updated overview of targeting PLK-1 for cancer therapy." @default.
• W2767793022 created "2017-11-17" @default.
• W2767793022 creator A5007020491 @default.
• W2767793022 creator A5023153969 @default.
• W2767793022 creator A5026128588 @default.
• W2767793022 creator A5027539618 @default.
• W2767793022 creator A5032939334 @default.
• W2767793022 creator A5033761941 @default.
• W2767793022 creator A5037323486 @default.
• W2767793022 creator A5040251206 @default.
• W2767793022 creator A5049727196 @default.
• W2767793022 creator A5067477167 @default.
• W2767793022 creator A5078255846 @default.
• W2767793022 date "2019-06-01" @default.
• W2767793022 modified "2023-10-03" @default.
• W2767793022 title "Molecular and enzoinformatics perspectives of targeting Polo-like kinase 1 in cancer therapy" @default.
• W2767793022 cites W1518200290 @default.
• W2767793022 cites W169077027 @default.
• W2767793022 cites W1774895213 @default.
• W2767793022 cites W1781336134 @default.
• W2767793022 cites W1916600850 @default.
• W2767793022 cites W1965111519 @default.
• W2767793022 cites W1968438075 @default.
• W2767793022 cites W1975776530 @default.
• W2767793022 cites W1982304115 @default.
• W2767793022 cites W1985694585 @default.
• W2767793022 cites W1987797033 @default.
• W2767793022 cites W1988974499 @default.
• W2767793022 cites W1997779012 @default.
• W2767793022 cites W2004981153 @default.
• W2767793022 cites W2020411912 @default.
• W2767793022 cites W2026609683 @default.
• W2767793022 cites W2035853571 @default.
• W2767793022 cites W2037874673 @default.
• W2767793022 cites W2040400275 @default.
• W2767793022 cites W2045726291 @default.
• W2767793022 cites W2048551141 @default.
• W2767793022 cites W2049613540 @default.
• W2767793022 cites W2055382176 @default.
• W2767793022 cites W2058727957 @default.
• W2767793022 cites W2059259335 @default.
• W2767793022 cites W2061646337 @default.
• W2767793022 cites W2071451207 @default.
• W2767793022 cites W2078308664 @default.
• W2767793022 cites W2083416032 @default.
• W2767793022 cites W2087036974 @default.
• W2767793022 cites W2090680566 @default.
• W2767793022 cites W2092307522 @default.
• W2767793022 cites W2102377211 @default.
• W2767793022 cites W2106391705 @default.
• W2767793022 cites W2107353013 @default.
• W2767793022 cites W2110864471 @default.
• W2767793022 cites W2124929823 @default.
• W2767793022 cites W2127019295 @default.
• W2767793022 cites W2130208791 @default.
• W2767793022 cites W2134694638 @default.
• W2767793022 cites W2135238345 @default.
• W2767793022 cites W2138129386 @default.
• W2767793022 cites W2155621461 @default.
• W2767793022 cites W2159817118 @default.
• W2767793022 cites W2164149367 @default.
• W2767793022 cites W2165291485 @default.
• W2767793022 cites W2285655259 @default.
• W2767793022 cites W2294442692 @default.
• W2767793022 cites W2329568476 @default.
• W2767793022 cites W2347151465 @default.
• W2767793022 cites W2401604490 @default.
• W2767793022 cites W2465286567 @default.
• W2767793022 cites W2531210814 @default.
• W2767793022 cites W2549761003 @default.
• W2767793022 cites W2551703932 @default.
• W2767793022 cites W2580398445 @default.
• W2767793022 cites W2589605115 @default.
• W2767793022 cites W2591477775 @default.
• W2767793022 cites W2605015597 @default.
• W2767793022 cites W2607555575 @default.
• W2767793022 cites W2619325549 @default.
• W2767793022 cites W2726132586 @default.
• W2767793022 cites W2755289999 @default.
• W2767793022 cites W3148618358 @default.
• W2767793022 doi "https://doi.org/10.1016/j.semcancer.2017.11.004" @default.
• W2767793022 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29122685" @default.
• W2767793022 hasPublicationYear "2019" @default.
• W2767793022 type Work @default.
• W2767793022 sameAs 2767793022 @default.
• W2767793022 citedByCount "22" @default.
• W2767793022 countsByYear W27677930222018 @default.
• W2767793022 countsByYear W27677930222019 @default.
• W2767793022 countsByYear W27677930222020 @default.
• W2767793022 countsByYear W27677930222021 @default.
• W2767793022 countsByYear W27677930222022 @default.
• W2767793022 countsByYear W27677930222023 @default.
• W2767793022 crossrefType "journal-article" @default.
• W2767793022 hasAuthorship W2767793022A5007020491 @default.
• W2767793022 hasAuthorship W2767793022A5023153969 @default.
• W2767793022 hasAuthorship W2767793022A5026128588 @default.
• W2767793022 hasAuthorship W2767793022A5027539618 @default.
• W2767793022 hasAuthorship W2767793022A5032939334 @default.

• next